Patent US4305944A successfully refreshed from Google Patents.
US4305944A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N-[(4-[3-cyano substituted pyridyl]piperazino)alkyl]-azaspirodecanediones
Assignee: Mead Johnson and Co LLC
•
Filing: 1980-09-08
•
Granted: 1981-12-15
•
Expires: 2000-09-08
Abstract
Abstract 2-[4-[4-(7,9-Dioxo-8-azaspiro[4.5]decan-8-yl)butyl]-1-piperazinyl]pyridine-3-carbonitrile, 2-[4-[4-(7,9-dioxo-8-azaspiro-[4.5]decan-8-yl)butyl]-3-methyl-1-piperazinyl]pyridine-3-carbonitrile and 8-[4-[4-(3-methoxy-2-pyridinyl)-1-piperazinyl]butyl]-8-azaspiro-[4.5]decane-7,9-dione are psychotropic compounds.
Inventors
- 👤 Davis L. Temple, Jr.
- 👤 Joseph P. Yevich
- 👤 Walter G. Lobeck, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 14:28
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/14; A; A61; A61P; A61P25/00; A61P25/18
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
42 words
A compound selected from the group consisting of those having the formula ##STR11## and the pharmaceutically acceptable acid addition salts thereof wherein R 1 and R 2 are selected from the group consisting of hydrogen and methyl, and R 3 is cyano.
Claim 2
Dependent Claim
42 words
A compound selected from the group consisting of those having the formula ##STR11## and the pharmaceutically acceptable acid addition salts thereof wherein R 1 and R 2 are selected from the group consisting of hydrogen and methyl, and R 3 is cyano.
Claim 3
Dependent Claim
14 words
The compound of claim 1, 2-[4-[4-(7,9-dioxo-8-azaspiro[4.5]decan-8-yl)butyl]-1-piperazinyl]pyridine-3-carbonitrile or a pharmaceutically acceptable acid addition salt thereof.
Claim 4
Dependent Claim
14 words
The compound of claim 1, 2-[4-[4-(7,9-dioxo-8-azaspiro[4.5]decan-8-yl)butyl]-3-methyl-1-piperazinyl]pyridine-3-carbonitrile or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
48 words
The process for eliciting a tranquilizer effect in a psychotic mammal which comprises administering to said mammal a non-toxic neuroleptically effective dose of from 0.01 to 40 mg/kg. of body weight of said mammal of a compound claimed in claim 1 by the oral or a parenteral route.
Claim 6
Dependent Claim
40 words
A method for the palliative treatment of neurosis in which anxiety symptoms are prominent which comprises administering a non-toxic anxiolytically effective dose of a compound claimed in claim 1 to a neurotic patient by the oral or a parenteral route.
Claim 7
Dependent Claim
47 words
A pharmaceutical composition in dosage unit form suitable for systemic administration to a mammalian host comprising a pharmaceutical carrier and an amount of a compound claimed in claim 1 to provide an effective daily dose of from 0.01 to 40 mg/kg. of body weight of said host.
Claim 8
Dependent Claim
14 words
The compound of claim 1, 2-[4-[4-(7,9-dioxo-8-azaspiro[4.5]decane-8-yl)butyl]-2-methyl-1-piperazinyl]pyridine-3-carbonitrile or a pharmaceutically acceptable acid addition salt thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-12-14 | 1985-06-15 | 1985-12-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-12-14 | 1989-06-15 | 1989-12-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-12-14 | 1993-06-15 | 1993-12-15 | $7700.00 | Window Closed / Lapsed |